Transcatheter aortic valve implantation (TAVI) has matured into a standard treatment option
for patients with severe symptomatic aortic valve stenosis (AS) across the whole spectrum of …

Background The impact of aortic valve replacement (AVR) on progression/regression of
extravalvular cardiac damage and its association with subsequent prognosis is unknown …

In this narrative review, we aim to summarize the literature surrounding the assessment and
management of the common, yet understudied combination of aortic stenosis (AS) and mitral …

Transcatheter therapies for the treatment of structural heart diseases (SHD) have expanded
dramatically over the last years, thanks to the developments and improvements of devices …

BACKGROUND Data on trends, predictors, and outcomes of heart failure (HF) readmissions
after transcatheter aortic valve replacement (TAVR) remain limited. Moreover, the …

Background There is little evidence about the prognostic role of mitral regurgitation (MR) in
patients with low‐flow, low‐gradient aortic stenosis undergoing transcatheter aortic valve …

Aortic stenosis is the most common valve disease requiring surgery or percutaneous
treatment. Since the first-in-man implantation in 2002 we have witnessed incredible …

Background Evidence about safety and efficacy of transcatheter aortic valve replacement
(TAVR) with the Venus A-Valve system (Venus Medtech, Hangzhou, China) remains limited …

Background Data on outcomes of transcatheter aortic valve replacement (TAVR) using
balloon-expandable valves (BEVs) or self-expandable valves (SEVs) as well as the impact …

The combination of aortic stenosis (AS) and mitral regurgitation (MR) is common in patients
with degenerative valvular disease. It is characterized by having complex pathophysiology …